Teclison Limited

We are on a mission to close critical gaps in cancer care by developing therapies that target well-understood biological pathways in which research has not yet yielded effective medicines. We are committed to pioneering new ways to effectively treat patients with solid tumor cancers who respond poorly to existing immunotherapies. We develop innovative cancer therapies to induce tumor necrosis and enhance antitumor immunity, offering cancer patients the hope of longer, better lives. Every day, we are exploring new ways to improve the lives of patients with solid tumor cancers. Our science and our culture are built on strategic collaboration and a deep commitment to improve treatment options for patients with cancer. Our scientists, advisors, and other experts leverage scientific innovation with pharmaceutical expertise to engineer groundbreaking therapies for solid tumor cancers with historically poor prognoses. Our team works at the leading edge of cancer immunotherapy, and we are committed to changing patient outcomes for the better. Our innovative platform radically remodels the tumor immune microenvironment of solid cancers, unlocking the ability to successfully treat cancer patients who respond poorly to existing immunotherapies.